Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10

Molecular Medicine Reports

Volumn 3, Issue 2, 2010, Pages 309-313

  Prokopiou, Ekatherine M ^a   Cooper, Patricia A ^a   Pettit, George R ^b   Bibby, Michael C ^a   Stevend, Shnyder D ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Auristatin PYE; Cisplatin; Colon adenocarcinoma; Combination therapy; Dolastatin 10; Pre clinical; Tubulin binder; Vascular disrupting agents

Indexed keywords

ANGIOGENESIS INHIBITOR; AURISTATIN PYE; CISPLATIN; DOLASTATIN 10; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

MUS;

EID: 77950852374     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr-00000256     Document Type: Article

References (36)

1. Hinnen P and Eskens FA: Vascular disrupting agents in clinical development. Br J Cancer 96: 1159-1165, 2007.
2. Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739, 2002.
3. Patterson DM, Charnley N, Saleem A, et al: Phase I evaluation of vascular disrupting agent OXi4503. J Clin Oncol 26: 3551, 2008.
4. Cooney MM, Savvides P, Agarwala S, et al: Phase II study of combretastatin A4 phosphate (CA 4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol 24: 5580, 2006.
5. LoRusso PM, Gadgeel SM, Wozniak A, et al: Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 26: 159-167, 2008.
6. Mauer AM, Cohen EE , Ma PC, et al: A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 3: 631-636, 2008.
7. Li J, Jameson MB, Baguley BC, Pili R and Baker SD: Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. Clin Cancer Res 14: 2102-2110, 2008.
8. Bai R, Roach MC, Jayaram SK, et al: Differential effects of active isomers, segments and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol 45: 1503-1515, 1993.
9. Bai RL , Pettit GR and Hamel E: Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265: 17141-17149, 1990.
10. Pettit GR, Kamano Y, Herald CL , et al: The isolation and structure of a remarkable murine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 109: 6883-6885, 1987.
11. Pettit GR: Dolastatin anticancer drugs. In: Marine Anticancer Compounds in the Era of Targeted Therapies. Chabner B (ed). Permanyer Publications, Barcelona, pp19-50, 2009.
12. Kalemkerian GP, Ou X, Adil MR, et al: Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 43: 507-515, 1999.
13. Mohammad RM, Pettit GR, Almatchy VP, Wall N, Varterasian M and Al-Katib A: Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma. Anticancer Drugs 9: 149-156, 1998.
14. Krug LM, Miller VA, Kalemkerian GP, et al: Phase II study of dolastatin-10 in patients with advanced non-small cell lung cancer. Ann Oncol 11: 227-228, 2000.
15. Vaishampayan U, Glode M, Du W, et al: Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res 6: 4205-4208, 2000.
16. Margolin K, Longmate J, Synold TW, et al: Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs 19: 335-340, 2001.
17. Saad ED , Kraut EH, Hoff PM, et al: Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol 25: 451-453, 2002.
18. Hoffman MA, Blessing JA and Lentz SS: A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 89: 95-98, 2003.
19. Perez EA, Hillman DW, Fishkin PA, et al: Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs 23: 257-261, 2005.
20. Kindler HL, Tothy PK, Wolff R, et al: Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs 23: 489-493, 2005.
21. Pettit GR, Srirangam JK, Barkoczy J, et al: Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anticancer Drug Des 10: 529-544, 1995.
22. Miyazaki K, Kobayashi M, Natsume T, et al: Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull 43: 1706-1718, 1995.
23. Harrigan GG, Luesch H, Yoshida WY, et al: Symplostatin 1: a dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J Nat Prod 61: 1075-1077, 1998.
24. Riely GJ, Gadgeel S, Rothman I, et al: A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 55: 181-185, 2007.
25. Fennell BJ, Carolan S, Pettit GR and Bell A: Effects of the antimitotic natural product dolastatin 10 and related peptides on the human malarial parasite Plasmodium falciparum. J Antimicrob Chemother 51: 833-841, 2003.
26. Shnyder SD, Cooper PA, Millington NJ, Pettit GR and Bibby MC: Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. Int J Oncol 31: 353-360, 2007.
27. Shnyder SD, Cooper PA, Gyselinck N, Hill BT, Double JA and Bibby MC: Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model. Anticancer Res 23: 4815-4820, 2003.
28. Shnyder SD, Cooper PA, Pettit GR, Lippert JW III and Bibby MC: Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res 23: 1619-1623, 2003.
29. Workman P, Twentyman P, Balkwill F, et al: United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR ) Guidelines for the Welfare of Animals in Experimental Neoplasia (2nd edition). Br J Cancer 77: 1-10, 1998.
30. Quinn PK, Bibby MC, Cox JA and Crawford SM: The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours. Br J Cancer 66: 323-330, 1992.
31. Smith KA, Hill SA, Begg AC and Denekamp J: Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 57: 247-253, 1988.
32. Kanthou C and Tozer GM: Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 90: 284-294, 2009.
33. Horsman MR and Siemann DW : Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66: 11520-11539, 2006.
34. Zweifel M, Jayson G, Reed N, et al: Combretastatin A-4 phosphate (CA 4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results. J Clin Oncol 27: 5502, 2009.
35. Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H and Hidalgo M: Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol 14: 1607-1615, 2003.
36. Siemann DW and Horsman MR: Vascular targeted therapies in oncology. Cell Tissue Res 335: 241-248, 2009.